poisar

Stocks · News reference

Radiopharm Theranostics Shares Data From Phase 1 Imaging Trial of RAD 301 In Healthy Volunteers And Subjects With Pancreatic Ductal Adenocarcinoma

Benzinga Newsdesk

RAD301 is a peptide-based molecule bound to Gallium-68 (Ga-68) that targets αvβ6-integrin, a cellular marker for tumor invasion and metastatic growth, the expression of which correlates with decreased survival in

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RADX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Radiopharm Theranostics

    Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

    Radiopharm Theranostics announced dosing of the first patient in the second cohort of its Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) at 70 mCi, following a positive recommendation from the Safety and Monitoring Committee. RV-01 is a 177Lutetium-tagged monoclonal antibody targeting B7-H3 in patients with B7-H3 expressing solid tumors, developed through a joint venture with MD Anderson Cancer Center.

    RADX